ibs.GRANADA scientists discover that an important protein in tumor prevention is epigenetically silenced in some leukemias

by Instituto de Investigación Biosanitaria - Ibs Granada

2 years ago
leukemia, Epigenetic silencing, BCL7A protein

It has been identified that the cells of some leukemias silence the production of the BCL7A protein, a protein that helps prevent cells from becoming tumorous.

Cancer cells resistant to treatment are already present before diagnosis of adult leukaemia

by IRB Barcelona - Instituto de Investigación Biomédica

4 years ago
genes, cells, diagnosis, leukemia, AECC

This work is a collaboration between Núria López-Bigas’ lab at IRB Barcelona and the groups headed by Anna Bigas (Hospital del Mar Medical Research Institute) and Josep Maria Ribera (Josep Carrera...

ORYZON holds its 4th annual Solidarity Day

by Oryzon Genomics

4 years ago
Solidarity Day, epigenetics, COVID 19, transfusions, blood bank, bone marrow, leukemia, iadademstat

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, celebrated yest...

ORYZON publishes paper in Journal of Clinical Oncology demonstrating relevance of iadademstat in leukemia

by Oryzon Genomics

4 years ago
iadademstat, leukemia, drug

Immuneel Therapeutics, Hospital Clínic de Barcelona & IDIBAPS Announce a Strategic collaboration & a License Agreement

by Fundació Clínic per a la Recerca Biomèdica

4 years ago
Immuneel Therapeutics, Hospital Clínic, IDIBAPS, leukemia, CAR-T therapy

Immuneel Therapeutics Private Limited (Immuneel) today announced that it has entered into a multi-asset collaboration and licensing agreement with Hospital Clínic de Barcelona (HCB) and Institut d’...

Artificial intelligence, a new tool against leukemia

by Hospital Universitari de Bellvitge

4 years ago
artificial intelligence, leukemia, La Caixa

Dr. Carolina M. Florian project has been selected by La Caixa Health Research grants

The Josep Carreras Institute creates a spin-off to develop therapies for leukaemia based on CAR–T

by Invivo Capital

4 years ago
Josep Carreras Foundation, Invivo Ventures, CDTI-Innvierte, OneChain Immunotherapeutics, CAR–T technology, leukemia, children

The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya's (Government of Catalonia) CERCA network, has created the OneChain Immunotherapeutics (OCI)...

Humanizing worms makes them sensitive to a cancer drug and identifies weak points of tumor cells

by Hospital Universitari de Bellvitge

5 years ago
nematode Caenorhabditis elegans, tumor cells, cells, cancer, leukemia, worms, biomedical research

At first glance, a one-millimeter worm that needs to be observed with a magnifying glass does not resemble a human being at all. However, the nematode Caenorhabditis elegans, an animal model widely us...

Rounds of funding, grants, pipeline advances, appointments and discoveries in leukemia

by Biocat

5 years ago
investment, leukemia, surgical robotics, platform, multiple sclerosis, dementia

Rounds at Ability, Elma and Vytrus and “la Caixa” grants, among the top headlines in September

The group of hematological neoplasms and hematopoietic transplantation of the IDIVAL published a study that linked high levels of the FANCA gene with a worse prognosis in chronic lymphatic leukemia

by Instituto de Investigación Marqués de Valdecilla

6 years ago
gene, FANCA, leukemia, CLL

Chronic Lymphatic Leukemia (CLL) is the most common type of leukemia in adults in the West. It mainly affects elderly patients and its incidence is expected to increase due to the progressive increase...

New immunotherapeutic strategy to treat T-cell acute lymphoblastic leukemia

by IrsiCaixa

6 years ago
immunotherapy, leukemia, T cells, virus

The study uses genetically modified immune cells that specifically target the CD1a molecule of the tumour cells, suggesting a new treatment with less adverse effects for patients

ORYZON to Present Clinical Data on LSD1 Inhibitor ORY-1001 at ASH 2016

by Oryzon Genomics

8 years ago
ORY-1001, Roche, Oryzon, leukemia

ORY - 1001 (RG6016), Oryzon’s first clinical asset, is a highly potent and selective Lysine Specific Demethylase - 1 (LSD1) inhibitor for the treatment of leukemia and other malignancies, currently ...